The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats

BACKGROUND: Sodium glucose co-transporter 2 inhibitor (SGLT2i), a new class of anti-diabetic drugs acting on inhibiting glucose resorption by kidneys, is shown beneficial in reduction of heart failure hospitalization and cardiovascular mortality. The mechanisms remain unclear. We hypothesized that S...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hsiang-Chun, Shiou, Yi-Lin, Jhuo, Shih-Jie, Chang, Chia-Yuan, Liu, Po-Len, Jhuang, Wun-Jyun, Dai, Zen-Kong, Chen, Wei-Yu, Chen, Yun-Fang, Lee, An-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444638/
https://www.ncbi.nlm.nih.gov/pubmed/30935417
http://dx.doi.org/10.1186/s12933-019-0849-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444638/
https://www.ncbi.nlm.nih.gov/pubmed/30935417
http://dx.doi.org/10.1186/s12933-019-0849-6

Ejemplares similares